News Release
No. 24007
June 24, 2024
Noile-Immune Biotech, Inc.
https://www.noile-immune.com

Return of NIB102 and NIB103 from Takeda
Noile-Immune Biotech, Inc. (hereinafter “Noile-Immune”) hereby announces that Noile-Immune has
recently completed discussions with Takeda Pharmaceutical Company Limited (hereinafter "Takeda") on thetransfer of data on NIB102 and NIB103, our in-house drug discovery pipelines, as informed on December 15,
2023 of returning the rights for the development and commercialization of them from Takeda which was thelicensee.
NIB102 and NIB103 are CAR-T cells against solid tumors, targeting GPC3 (Glypican-3) and Mesothelin
respectively, and both are development pipelines incorporating Noile-Immune's own PRIME technology(Proliferation-inducing and migration-enhancing technology). For more information on NIB102 and NIIB103,and PRIME technology, please see the following page. While the clinical trials of these pipelines have been
conducted as Takeda's development code of TAK-102 and TAK-103 respectively, the transfer of data etc. which
are transferable at this time has been completed.
As a result of the return of both pipelines, new patients will not be enrolled in the Phase I trials that werebeing conducted by Takeda, and these clinical trials will be monitored under Takeda's control until the end of
the follow-up period after the administrations. Therefore, Noile-Immune will not incur any financial burdens
related to the termination of these Phase I trials.
Publication of the data obtained so far will be considered, such as conference presentations in the future,
based on the policy of Takeda and Noile-Immune. In regard to TAK-102, data on the Phase I trial was presented
at the American Society of Clinical Oncology (ASCO) held from May 31 to June 4, 2024 (please refer to thepress release issued by Noile-Immune on June 4, 2024).
The cancellation fees were arranged to fluctuate depending on the details of the costs incurred by Takeda forthe development to date, but as a result of the calculation, any cancellation fees did not occur. With respect toNIB103, if Noile-Immune uses Takeda's own proprietary intellectual property in the future, Noile-Immune will
pay Takeda royalties in low single digits after the launch.
There are no special provisions regarding the handling of the 8,119,800 shares (18.76%) of Noile-Immune'sstocks held by Takeda.
Noile-Immune does not anticipate any impact on the financial results for the fiscal year ended December 31,2024 due to this transaction.
As a result of the completion of the transfer from Takeda, Noile-Immune holds NIB101, NIB102 and NIB103
as development pipelines in the clinical stage, and NIB104 and NIB105 (target molecules of these products arenot disclosed) as development pipelines in the non-clinical stage, in Noile-Immune's own in-house CAR-T
1 /3

assets with PRIME technology against solid tumors. Noile-Immune will review each development pipeline,including the clinical data of NIB102 and NIB103 clinical trials, transferred from Takeda, and re-prioritize ourin-house drug discovery pipelines which Noile-Immune will promote the clinical developments from now on.
The details of development strategies will be announced as soon as they are determined.

【NIB-102】
NIB102 is a CAR-T cell with Noile-Immune's proprietary PRIME technology and is an autologous PRIMECAR-T cell that uses cancer patients' own lymphocytes. NIB102 targets GPC3 (Glypican-3), which is expressedin some of hepatocellular carcinoma, stomach cancer, and NSCLCsq, and it is estimated that the potential target
population is approximately 35,000 patients per year in Japan and approximately 197,000 patients per year
including those overseas.
【NIB-103】
NIB103 is a CAR-T cell with Noile-Immune's proprietary PRIME technology and is an autologous PRIMECAR-T cell that uses cancer patients' own lymphocytes. NIB103 targets mesothelin, which is expressed in someof triple negative breast cancer (TNBC), colorectal cancer, ovarian cancer, and pancreatic cancer, and it isestimated that the potential population is approximately 60,000 patients per year in Japan and approximately
367,000 patients per year including those overseas.

【PRIME technology】
PRIME technology is Noile-Immune's proprietary technology which further improves immune cells, such as
CAR-T cells used for anti-cancer therapy, to produce interleukin-7 (IL-7) and CCL19, and has a potential topromote the growth and survival of T cells and to stimulate the migration of T cells and dendritic cells, so as toenhance the therapeutic effects against cancer. PRIME technology was developed to create an environment
conducive to attacking cancer cells efficiently by inducing accumulation of a large number of CAR-T cells andbody’s immune cells at the site of cancer.
For more details, please visit https://www.noile-immune.com/en/Our_Science/prime_car-t.html.

【Noile-Immune Biotech, Inc.】
Noil Immune Biotech, Inc. (TSE: 4893) is a biotech company, an academia start-up, and is committed to thepractical application of next-generation immunotherapy for solid cancers by utilizing PRIME CAR-T cells
which incorporate Noile-Immune's proprietary PRIME technology, an innovative approach to enhance thetherapeutic effects of immune cell therapy. As PRIME technology can be combined with various chimericantigen receptors (CARs) to create novel drugs and applied to a broad range of modalities, it is expected todevelop many anti-cancer therapeutic approaches in combination with other technologies in the future. Throughour business activities, Noile-Immune aims to contribute to the creation of a society that can overcome cancer.
For more information, please visit https://www.noile-immune.com/en.html.

2 /3

Contact for inquiries or additional information
2-12-10 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan
Noile-Immune Biotech, Inc.
E-mail: ir@noile-immune.com

3 /3